JW Pharmaceutical Past Earnings Performance
Past criteria checks 6/6
JW Pharmaceutical has been growing earnings at an average annual rate of 72.2%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 9.2% per year. JW Pharmaceutical's return on equity is 24.2%, and it has net margins of 9.9%.
Key information
72.2%
Earnings growth rate
72.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 9.2% |
| Return on equity | 24.2% |
| Net Margin | 9.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How JW Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 736,543 | 72,893 | 202,526 | 34,814 |
| 30 Jun 24 | 742,090 | 35,136 | 202,693 | 34,503 |
| 31 Mar 24 | 755,737 | 40,621 | 206,956 | 33,428 |
| 31 Dec 23 | 748,527 | 36,489 | 205,240 | 33,671 |
| 30 Sep 23 | 736,668 | 25,076 | 202,026 | 36,230 |
| 30 Jun 23 | 722,312 | 51,278 | 200,738 | 36,842 |
| 31 Mar 23 | 701,393 | 36,949 | 197,326 | 34,471 |
| 31 Dec 22 | 684,351 | 31,892 | 193,728 | 33,736 |
| 30 Sep 22 | 660,661 | 12,130 | 194,086 | 25,914 |
| 30 Jun 22 | 639,806 | 8,930 | 185,239 | 22,424 |
| 31 Mar 22 | 620,832 | 4,584 | 183,461 | 21,490 |
| 31 Dec 21 | 606,585 | -968 | 183,645 | 19,884 |
| 30 Sep 21 | 581,827 | -1,190 | 176,948 | 22,478 |
| 30 Jun 21 | 569,978 | -3,329 | 172,804 | 21,680 |
| 31 Mar 21 | 560,407 | -8,469 | 162,051 | 22,653 |
| 31 Dec 20 | 547,336 | -15,241 | 155,905 | 22,943 |
| 30 Sep 20 | 516,529 | -31,512 | 158,290 | 22,341 |
| 30 Jun 20 | 512,402 | -33,320 | 157,829 | 23,165 |
| 31 Mar 20 | 510,079 | -23,341 | 157,596 | 24,833 |
| 31 Dec 19 | 511,335 | -25,275 | 154,914 | 25,220 |
| 30 Sep 19 | 524,767 | -9,432 | 143,381 | 24,775 |
| 30 Jun 19 | 538,269 | -8,270 | 143,598 | 24,211 |
| 31 Mar 19 | 536,808 | -659 | 145,943 | 21,480 |
| 31 Dec 18 | 537,182 | 8,057 | 147,747 | 21,268 |
| 30 Sep 18 | 534,919 | 9,113 | 156,260 | 20,473 |
| 30 Jun 18 | 521,666 | 12,567 | 155,566 | 20,479 |
| 31 Mar 18 | 510,284 | 2,417 | 150,694 | 21,457 |
| 31 Dec 17 | 502,919 | -742 | 144,933 | 21,982 |
| 30 Sep 17 | 490,656 | 14,223 | 137,106 | 21,134 |
| 30 Jun 17 | 476,290 | 3,697 | 135,734 | 20,832 |
| 31 Mar 17 | 471,517 | -11,472 | 133,904 | 18,586 |
| 31 Dec 16 | 467,465 | -10,934 | 130,801 | 18,005 |
| 30 Sep 16 | 460,523 | -18,836 | 131,003 | 17,625 |
| 30 Jun 16 | 452,150 | -12,991 | 127,792 | 17,210 |
| 31 Mar 16 | 447,417 | 2,860 | 124,501 | 17,318 |
| 31 Dec 15 | 434,352 | 1,921 | 122,618 | 16,480 |
| 30 Sep 15 | 447,788 | 1,575 | 128,008 | 16,802 |
| 30 Jun 15 | 439,802 | 1,064 | 126,024 | 16,705 |
| 31 Mar 15 | 426,011 | -3,378 | 123,767 | 17,390 |
| 31 Dec 14 | 412,791 | -2,357 | 120,558 | 17,482 |
| 30 Sep 14 | 386,064 | -2,651 | 109,760 | 16,720 |
| 30 Jun 14 | 386,067 | -2,648 | 105,446 | 15,722 |
| 31 Mar 14 | 395,535 | 3,095 | 104,643 | 14,894 |
| 31 Dec 13 | 394,182 | 2,275 | 105,119 | 13,464 |
Quality Earnings: A001065 has high quality earnings.
Growing Profit Margin: A001065's current net profit margins (9.9%) are higher than last year (3.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A001065 has become profitable over the past 5 years, growing earnings by 72.2% per year.
Accelerating Growth: A001065's earnings growth over the past year (190.7%) exceeds its 5-year average (72.2% per year).
Earnings vs Industry: A001065 earnings growth over the past year (190.7%) exceeded the Pharmaceuticals industry 20.6%.
Return on Equity
High ROE: A001065's Return on Equity (24.2%) is considered high.